Cargando…

Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts

Aging is a major risk factor for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). As metabolic alterations are a hallmark of aging and have previously been observed in ALS, it is important to examine the effect of aging in the context of ALS metabolic function. Here, using...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerou, Margarita, Hall, Benjamin, Woof, Ryan, Allsop, Jessica, Kolb, Stephen J., Meyer, Kathrin, Shaw, Pamela J., Allen, Scott P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346650/
https://www.ncbi.nlm.nih.gov/pubmed/34044197
http://dx.doi.org/10.1016/j.neurobiolaging.2021.04.013
_version_ 1783734921987096576
author Gerou, Margarita
Hall, Benjamin
Woof, Ryan
Allsop, Jessica
Kolb, Stephen J.
Meyer, Kathrin
Shaw, Pamela J.
Allen, Scott P.
author_facet Gerou, Margarita
Hall, Benjamin
Woof, Ryan
Allsop, Jessica
Kolb, Stephen J.
Meyer, Kathrin
Shaw, Pamela J.
Allen, Scott P.
author_sort Gerou, Margarita
collection PubMed
description Aging is a major risk factor for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). As metabolic alterations are a hallmark of aging and have previously been observed in ALS, it is important to examine the effect of aging in the context of ALS metabolic function. Here, using a newly established phenotypic metabolic approach, we examined the effect of aging on the metabolic profile of fibroblasts derived from ALS cases compared to controls. We found that ALS fibroblasts have an altered metabolic profile, which is influenced by age. In control cases, we found significant increases with age in NADH metabolism in the presence of several metabolites including lactic acid, trehalose, uridine and fructose, which was not recapitulated in ALS cases. Conversely, we found a reduction of NADH metabolism with age of biopsy, age of onset and age of death in the presence of glycogen in the ALS cohort. Furthermore, we found that NADH production correlated with disease progression rates in relation to a number of metabolites including inosine and α-ketoglutaric acid. Inosine or α-ketoglutaric acid supplementation in ALS fibroblasts was bioenergetically favourable. Overall, we found aging related defects in energy substrates that feed carbon into glycolysis at various points as well as the tricarboxylic acid (TCA) cycle in ALS fibroblasts, which was validated in induced neuronal progenitor cell derived iAstrocytes. Our results suggest that supplementing those pathways may protect against age related metabolic dysfunction in ALS.
format Online
Article
Text
id pubmed-8346650
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83466502021-09-01 Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts Gerou, Margarita Hall, Benjamin Woof, Ryan Allsop, Jessica Kolb, Stephen J. Meyer, Kathrin Shaw, Pamela J. Allen, Scott P. Neurobiol Aging Article Aging is a major risk factor for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). As metabolic alterations are a hallmark of aging and have previously been observed in ALS, it is important to examine the effect of aging in the context of ALS metabolic function. Here, using a newly established phenotypic metabolic approach, we examined the effect of aging on the metabolic profile of fibroblasts derived from ALS cases compared to controls. We found that ALS fibroblasts have an altered metabolic profile, which is influenced by age. In control cases, we found significant increases with age in NADH metabolism in the presence of several metabolites including lactic acid, trehalose, uridine and fructose, which was not recapitulated in ALS cases. Conversely, we found a reduction of NADH metabolism with age of biopsy, age of onset and age of death in the presence of glycogen in the ALS cohort. Furthermore, we found that NADH production correlated with disease progression rates in relation to a number of metabolites including inosine and α-ketoglutaric acid. Inosine or α-ketoglutaric acid supplementation in ALS fibroblasts was bioenergetically favourable. Overall, we found aging related defects in energy substrates that feed carbon into glycolysis at various points as well as the tricarboxylic acid (TCA) cycle in ALS fibroblasts, which was validated in induced neuronal progenitor cell derived iAstrocytes. Our results suggest that supplementing those pathways may protect against age related metabolic dysfunction in ALS. Elsevier 2021-09 /pmc/articles/PMC8346650/ /pubmed/34044197 http://dx.doi.org/10.1016/j.neurobiolaging.2021.04.013 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gerou, Margarita
Hall, Benjamin
Woof, Ryan
Allsop, Jessica
Kolb, Stephen J.
Meyer, Kathrin
Shaw, Pamela J.
Allen, Scott P.
Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts
title Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts
title_full Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts
title_fullStr Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts
title_full_unstemmed Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts
title_short Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts
title_sort amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346650/
https://www.ncbi.nlm.nih.gov/pubmed/34044197
http://dx.doi.org/10.1016/j.neurobiolaging.2021.04.013
work_keys_str_mv AT geroumargarita amyotrophiclateralsclerosisaltersthemetabolicagingprofileinpatientderivedfibroblasts
AT hallbenjamin amyotrophiclateralsclerosisaltersthemetabolicagingprofileinpatientderivedfibroblasts
AT woofryan amyotrophiclateralsclerosisaltersthemetabolicagingprofileinpatientderivedfibroblasts
AT allsopjessica amyotrophiclateralsclerosisaltersthemetabolicagingprofileinpatientderivedfibroblasts
AT kolbstephenj amyotrophiclateralsclerosisaltersthemetabolicagingprofileinpatientderivedfibroblasts
AT meyerkathrin amyotrophiclateralsclerosisaltersthemetabolicagingprofileinpatientderivedfibroblasts
AT shawpamelaj amyotrophiclateralsclerosisaltersthemetabolicagingprofileinpatientderivedfibroblasts
AT allenscottp amyotrophiclateralsclerosisaltersthemetabolicagingprofileinpatientderivedfibroblasts